Comparison of 60 and 80 mg/m(2) of daunorubicin in induction therapy of acute myeloid leukaemia.
Vaezi M, Bahar B, Mousavi A, Yaghmai M, Kasaeian A, Souri M, Jahani M, Alimoghaddam K, Ghavamzadeh A.
Vaezi M, et al.
Hematol Oncol. 2017 Mar;35(1):101-105. doi: 10.1002/hon.2236. Epub 2015 Aug 3.
Hematol Oncol. 2017.
PMID: 26386260
Clinical Trial.
Total of 114 patients were included in the study. Fifty-five patients received 60 mg/m(2) of daunorubicin (arm 1) 1 h IV infusion for 3 days, and the remaining 59 received 80 mg/m(2) (arm 2) 1 h IV infusion for 3 days. ...Considering these results, we found that 60 …
Total of 114 patients were included in the study. Fifty-five patients received 60 mg/m(2) of daunorubicin (arm 1) 1 h IV infusion for …